Business Context and Reporting Period
Company: Aurinia Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2026
Event: Announcement of a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation regarding Teva's Abbreviated New Drug Application (ANDA) for generic 7.9 mg voclosporin oral capsules in the United States.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a legal settlement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the resolution of ongoing patent litigation with Teva Pharmaceuticals Inc. regarding the generic version of the Company's voclosporin product. The specific financial terms of the settlement or the impact on future revenue streams are not detailed in this filing text.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the settlement, which is incorporated by reference.
- Risks and Contingencies: The filing addresses the resolution of a specific legal contingency (patent infringement litigation). The text includes standard disclaimers stating that the information is summary in nature and the Company undertakes no obligation to update the information except as required by law.
- Unusual Items: None reported beyond the settlement event.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific financial terms of the settlement with Teva.
- Determine the agreed-upon market entry date for Teva's generic voclosporin capsules.
- Assess the potential impact of the settlement on Aurinia's future revenue projections for voclosporin.
- Verify if the settlement includes any royalty payments or upfront cash considerations.